FLOVENT AND FLONASE HIGHLIGHT NEW PRODUCT FLOW AMONG GLAXO's RESPIRATORY PRODUCTS; GENERATIONAL CHANGE IS SMOOTH IN THAT SEGMENT
Executive Summary
Flovent inhaler and Flonase nasal spray continue to lead the new product flow in Glaxo's respiratory line as it faces major patent expiration challenges across its product portfolio. Flovent (fluticasone propionate, known outside the U.S. as Flixotide) worldwide sales doubled to $226.6 mil. from $114.1 mil. for the first half of the year, and Flonase (fluticasone in a nasal spray, Flixonase) sales grew 12.6% to $174.4 mil.